HIV/AIDS
AHF Welcomes FDA Approval of Pfizer's Selzentry; Urges Industry to Show Restraint Pricing Newest AIDS Drugs
Published in AIDS Weekly, August 20th, 2007
On the heels of the fourth International AIDS Society's Conference on HIV Pathogenesis, Treatment and Prevention, which took place in Sydney in late July, AIDS Healthcare Foundation (AHF) welcomed yesterday's news that the FDA has approved Pfizer Inc.'s new AIDS salvage therapy, Selzentry (maraviroc), a different class of new antiretroviral AIDS drug which had been discussed and presented at the IAS conference. However, AHF urged both Pfizer and the pharmaceutical industry as a whole to show some restraint as companies set prices for several new AIDS drugs that are expected to come to market over the next year. Pfizer announced that it plans to make this latest AIDS treatment available by...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-08-20)
More Articles from AIDS Weekly
- HIV/AIDS
Abstinence programs fail to cut risk of HIV infection - HIV/AIDS
Research Spotlights TV Portrayal of Organ Donations, Spurs Advocates - Cancer Vaccines
Nanotherapeutics and the Vaccine Branch of the National Cancer Institute Enter Into Cooperative Research and Development Agreement (CRADA) - HIV/AIDS
Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test - HIV/AIDS
AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India: 'Profit at What Cost? AIDS Drugs for All' - HIV/AIDS
Entry of New Drug Classes Redefining the HIV Market - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
